Tianjin, 6 February 2025 - CanSino Biologics Inc (“CanSinoBIO” or “the Company”) is pleased to announce that the National Medical Products Administration of the People’s Republic of China (NMPA) has granted a notice of acceptance to our new drug application for the absorbed tetanus vaccine (the “Tetanus Vaccine”) developed by the Company.

Tetanus is an acute infectious disease, with a mortality rate reaching 30%-50%. Without medical intervention, the mortality rate of tetanus approaches 100%, highlighting the urgent need for effective prevention.

In response to this significant health challenge, the Company has developed the Tetanus Vaccine, using an animal-free culture medium for fermentation, enhancing its safety profile. We have successfully identified stable industrial-scale processes for its production. This vaccine primarily targets the prevention of non-neonatal tetanus, thereby expanding the Company’s pipeline and strengthening its core competitiveness.

This acceptance marks a pivotal step in CanSinoBIO’s mission to combat severe infectious diseases, and underscores our commitment to advancing public health through innovative, high-quality and affordable solutions.